Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

Detailed price information for Dynavax Technologies (DVAX-Q) from The Globe and Mail including charting and trades.

The company faces challenges in developing a single-dose shingles vaccine candidate that meets non-inferiority margins compared to Shingrix. Q: With the updated 2030 market view, does the previous ...

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of ...

which is currently being used in such vaccines as GSK’s Shingrix for shingles, Arexvy for RSV, Novavax’s COVID-19 vaccine, and others. “We’re a pretty new company to the space of vaccine ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Nov 6 (Reuters) - An initial 899,000 vaccine doses have been allocated for 9 countries across Africa that have been hit hard by the current mpox surge, the WHO and other health organisations said ...

Jefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...